Reaching Your Goal Weight on Wegovy, Zepbound or Ozempic: What Maintenance Looks Like

Reaching the weight you were aiming for on semaglutide (Wegovy) or tirzepatide (Zepbound) doesn’t end treatment on its own. Both US labels approve the drug to reduce excess body weight and maintain weight reduction long term, and neither sets an end date^[1,2]. In the trials, people who stayed on the drug kept the weight off for years. For lowering the dose, I found exactly one published trial, SURMOUNT-MAINTAIN, with tirzepatide: it kept more weight off than placebo, but less than staying on the higher dose^[4]. For semaglutide, or for spacing out doses, there are no trial results.Dotted underline: a drug-label fact; hover over it to see the date it was checked.

This guide is about life on treatment once you’ve reached your goal. What happens when you stop is in what happens when you stop Ozempic, Wegovy or Zepbound, and how to think about a goal at all is in ideal weight: what to look at instead. Your maintenance dose, and whether you continue, change or stop, is a decision you make with your prescriber.

What the US labels say about staying on treatment

I checked the labels on DailyMed on October 5, 2026:

Saxenda’s 4% rule is an early check on whether the drug is working, not a rule for what to do at goal weight. Liraglutide has its own guide. Ozempic is approved for type 2 diabetes, not weight management; the differences are in the semaglutide guide.

Two details worth knowing:

• “Maintenance dosage” doesn’t mean “the dose for when you reach your goal.” In the labels, it’s the dose you reach after the initial step-up, and both list more than one. Both also say to consider treatment response and tolerability when selecting the maintenance dosage^[1,2]. Which one is yours is your prescriber’s call.
• No label describes lowering or spacing doses because you’ve reached a weight. Zepbound’s only provision is about tolerability: if patients do not tolerate a maintenance dosage, consider a lower maintenance dosage^[2]. For Saxenda in adults, lower dosages are for titration only^[3].

What the trials show when people stay on the drug

On the drug, weight holds for years

• Semaglutide. In SELECT (summary), with 17,604 adults with cardiovascular disease, overweight or obesity and no diabetes, weight loss continued to week 65 and then held through week 208. At four years, weight was 10.2% below the starting point, vs. 1.5% on placebo^[9].
• Tirzepatide. Among the 1,032 SURMOUNT-1 participants with prediabetes, treated for 176 weeks, weight was still 12.3%, 18.7% and 19.7% below baseline on 5, 10 and 15 mg, vs. 1.3% on placebo^[10].

Before that, weight stops falling: in an analysis of SURMOUNT-1, nearly 9 in 10 people who stayed on tirzepatide and lost at least 5% had reached a plateau by week 72^[11]. That’s expected. When it usually happens, and how to tell a plateau from your finish line, is in GLP-1 weight plateau.

Staying on vs. stopping: STEP 4 and SURMOUNT-4

In both trials, everyone took the drug for several months and then was randomly assigned to continue or switch to placebo. In STEP 4 (summary), people who stayed on semaglutide lost another 7.9% between weeks 20 and 68^[7]. In SURMOUNT-4 (summary), people who stayed on tirzepatide lost another 5.5%, and 89.5% kept at least 80% of the weight they’d lost, vs. 16.6% on placebo^[8]. The placebo groups are covered in the stopping guide.

Stepping down the dose: SURMOUNT-MAINTAIN

This is the first published trial to compare staying on a high dose, lowering it, or stopping. SURMOUNT-MAINTAIN (summary) enrolled 441 adults with obesity at 20 US sites; per its published design, people with type 2 diabetes were excluded^[5]. Everyone took tirzepatide for 60 weeks at their maximum tolerated dose (10 or 15 mg). Then 378 were randomized for 52 weeks^[4]:

From week 84, rescue treatment was offered to anyone who had regained more than half of the weight they’d lost^[4]. The authors conclude that stepping down to 5 mg might be an alternative to stopping, though individual responses may vary^[4]. Eli Lilly funded it, and it ran for one year after the switch.

Switching to a pill: ATTAIN-MAINTAIN

In ATTAIN-MAINTAIN (summary), 376 adults coming off 72 weeks of injectable tirzepatide or semaglutide switched to orforglipron, a once-daily GLP-1 pill, or to placebo. Among those who had plateaued, orforglipron kept 74.7% of the weight lost on tirzepatide (placebo: 49.2%) and 79.3% of the weight lost on semaglutide (placebo: 37.6%)^[6]. No group stayed on the injection, so it can’t tell you whether the pill holds weight as well as continuing the shot^[6]. The pill is covered in the orforglipron (Foundayo) guide.

Spacing out doses: one case series

Taking the shot every other week comes up a lot. The only publication I found is a 2026 case series: 30 adults at a San Diego obesity practice who, once they’d plateaued, kept their dose but took it less often, usually every other week. Over about 36 weeks, average weight went from 74.1 to 72.4 kg (163.4 to 159.6 lb)^[13]. It’s retrospective, small and uncontrolled, so it can’t tell you whether this works or for whom.

The OFF-RAMP pilot trial at the University of Pittsburgh will compare, in 60 people, staying on the full dose, tapering dose and frequency, or switching treatment. As of October 5, 2026, it wasn’t recruiting yet^[14]. And the Wegovy label says: if 2 or more consecutive doses of WEGOVY injection are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal side effects^[1]: skipping doses isn’t a neutral way to “maintain.”

What we still don’t know

• I found no trials with results on a lower semaglutide dose for maintenance, or on spacing doses (PubMed and ClinicalTrials.gov, October 5, 2026).
• The longest on-drug data run about four years (SELECT) and three (SURMOUNT-1)^[9,10], and almost all of these trials were funded by Novo Nordisk or Eli Lilly.

Hunger at goal weight

Does hunger come back while you’re still on the drug? There’s little measured data. In a subgroup of STEP 5, 174 people filled out a control-of-eating questionnaire. The difference from placebo in hunger and fullness was clear at week 20 but not at weeks 52 and 104; craving control and savory cravings were still better than on placebo^[12]. In other words, the edge on hunger faded over time, and the edge on cravings faded less. It’s a subgroup, without correction for multiple comparisons: a clue, not a conclusion.

What food noise is and what helps is in food noise, and what to check when hunger gets loud is in still hungry on Ozempic or Mounjaro. If the change is big, talk to your prescriber rather than adjusting the dose yourself.

Eating at maintenance: a bit more than while losing, less than before

While your weight is falling, you eat less than you burn; once it’s stable, the two match. A model led by an NIH researcher puts a number on it: each pound of stable weight difference changes daily energy needs by about 10 kcal (about 100 kJ per kilogram). And a change in eating takes a while to show: half the effect on weight arrives in about a year, 95% in about three^[16]. It’s an average, not your number, but it explains why you can eat a bit more than while losing, and less than before treatment.

What has support for this phase, according to the 2025 joint advisory from four US medical and nutrition societies:

• Habits. In the National Weight Control Registry, keeping weight off is linked with eating at regular times, eating breakfast, choosing minimally processed foods with fiber and protein, avoiding sugary drinks, and allowing occasional portion-controlled treats instead of severe restriction^[15]. These are observational data.
• Protein. The advisory cites 0.8 g per kilogram a day (0.36 g per pound) for the general population and 1.2 to 1.6 g/kg (0.54 to 0.73 g per pound) during active weight loss; it gives no separate figure for maintenance^[15]. You can estimate yours with the protein calculator, and there’s more in protein and muscle on GLP-1 medications.
• Strength training. At least three sessions a week, plus at least 150 minutes of moderate aerobic activity, to preserve muscle and bone^[15]. There’s a starter plan in strength training on GLP-1 medications, and how to track body composition is in bioimpedance scale vs. DEXA.
• Fiber. It’s on the same registry list, alongside protein^[15]. The fiber calculator and soluble vs. insoluble fiber can help you check how much you get.

What isn’t a good idea is cutting back further to “lock in” the weight. If eating has become a source of anxiety, talk to your doctor or a registered dietitian.

A range, not an exact number

Weight moves even when nothing changes. In a European study of more than 1,000 people maintaining a weight loss, weight swung about 0.35% within each week and rose an average of 1.35% over Christmas^[18]. One group of researchers proposed defining long-term maintenance as a change of less than 3% of body weight^[17], and the tirzepatide and orforglipron trials called a change of less than 5% over 12 weeks a plateau^[6,11].

That’s why it makes more sense to agree on a range with your prescriber than on a single number, along with what change, up or down, should prompt an earlier visit. Weighing yourself often can help, but only if it doesn’t make you anxious.

When to call your prescriber without waiting for your next visit

You can bring your questions with the doctor visit checklist and log symptoms in the symptom diary.

What maintenance costs

Maintaining on the drug means paying for it with no end date. I don’t repeat prices because they change, and what you pay depends on your plan. The monthly cost calculator shows dated list prices with sources per dose, per 4 weeks and per year, and Mounjaro vs. Zepbound explains why I don’t rank brands by price.

Stopping is a decision you make with your prescriber

The 2025 advisory notes that ongoing GLP-1 therapy is recommended for obesity control and weight maintenance, and that most people prescribed these drugs for obesity stop within a year. It adds that some of that may come from low awareness that treatment is long term even after a weight goal or a plateau is reached^[15]. There can be good reasons to raise it, such as side effects, cost or a planned pregnancy. How and when is decided with your prescriber, knowing what the withdrawal trials show.

Frequently asked questions

Do you have to stay on the medication for life?

Nobody knows yet. The Wegovy and Zepbound labels set no time limit^[1,2], and the longest trials ran three and four years, with weight holding steady while people stayed on the drug^[9,10]. The SURMOUNT-MAINTAIN authors conclude that long-term treatment is often necessary to maintain weight reduction^[4]. Beyond that there’s no data; the decision is yours and your prescriber’s.

Can you lower the dose once you reach your goal?

No label describes lowering it because you’ve reached a weight. The labels list more than one maintenance dose and say to weigh response and tolerability; Zepbound adds a lower maintenance dose if one isn’t tolerated^[1,2]. In SURMOUNT-MAINTAIN, stepping down to 5 mg kept more weight off than placebo and less than staying on the higher dose^[4]. There are no published trials with semaglutide. Any change is your prescriber’s call.

Can you eat more now that you’re not losing?

Somewhat more than while you were losing, yes, because you’re no longer eating below what you burn. But a smaller body burns less: about 10 kcal a day less for every pound lost, per the NIH model^[16]. What has the most support is eating at regular times, prioritizing protein and fiber, and strength training^[15]. A registered dietitian can help you fine-tune amounts.